199 related articles for article (PubMed ID: 22267716)
1. Administration of voriconazole in patients with renal dysfunction.
Neofytos D; Lombardi LR; Shields RK; Ostrander D; Warren L; Nguyen MH; Thompson CB; Marr KA
Clin Infect Dis; 2012 Apr; 54(7):913-21. PubMed ID: 22267716
[TBL] [Abstract][Full Text] [Related]
2. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function.
Alvarez-Lerma F; Allepuz-Palau A; Garcia MP; Angeles Leon M; Navarro A; Sanchez-Ruiz H; Iruretagoyena JR; Luque-Gomez P;
J Chemother; 2008 Feb; 20(1):93-100. PubMed ID: 18343750
[TBL] [Abstract][Full Text] [Related]
3. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.
von Mach MA; Burhenne J; Weilemann LS
BMC Clin Pharmacol; 2006 Sep; 6():6. PubMed ID: 16981986
[TBL] [Abstract][Full Text] [Related]
5. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of intravenous voriconazole in patients with compromised renal function.
Lilly CM; Welch VL; Mayer T; Ranauro P; Meisner J; Luke DR
BMC Infect Dis; 2013 Jan; 13():14. PubMed ID: 23320795
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
9. Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice.
Heinz WJ; Silling G; Böhme A
Curr Med Res Opin; 2011 Feb; 27(2):335-42. PubMed ID: 21155707
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.
Oude Lashof AM; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Schlamm HT; Rex JH; Kullberg BJ
Antimicrob Agents Chemother; 2012 Jun; 56(6):3133-7. PubMed ID: 22450974
[TBL] [Abstract][Full Text] [Related]
11. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
Abel S; Allan R; Gandelman K; Tomaszewski K; Webb DJ; Wood ND
Clin Drug Investig; 2008; 28(7):409-20. PubMed ID: 18544001
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
16. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
17. Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.
Frick MA; Soler-Palacín P; Martín Nalda A; Guarner ME; Nadal CF
Pediatr Infect Dis J; 2010 May; 29(5):480-1. PubMed ID: 20431387
[No Abstract] [Full Text] [Related]
18. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
[TBL] [Abstract][Full Text] [Related]
19. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
